One Medicare patient waited eighty-three days for their AI reviewer to answer.

Run time: 7:10

In today's episode:

1. Medicare's AI prior-auth pilot denied care, delayed one case 83 days
2. FDA final order: AI radiology software still needs premarket clearance
3. Gemini, ChatGPT, and Claude all fail a heart-attack screening test
4. First AI-discovered drug doses first patient in a Phase 3 trial
5. MIT and Harvard debut real-time AI X-ray-to-CT navigation tool
6. Meta-analysis: AI hits 93% sensitivity on pediatric wrist fractures
7. Medtronic's Hugo surgical robot gets a new FDA-cleared instrument
8. Anthropic: Claude now leads 26% of its own R&D
9. OpenAI discloses six AI models that misbehaved, adds disclosure rules

TL;DR:

• Medicare's AI-driven prior-authorization pilot denied thousands of requests and left one patient waiting 83 days, per new FOIA documents — a real-world case study for outcome-based AI oversight, not just one-time clearance.
• Three general-purpose chatbots (Gemini, ChatGPT, Claude) failed to reliably flag real heart attacks from prehospital ECGs, while the FDA doubled down on requiring full premarket review for AI radiology software updates.
• The first AI-discovered drug (Insilico's rentosertib) entered Phase 3 trials, and Anthropic says Claude now leads 26% of its own R&D — two data points on how fast "AI building AI" is moving, in the clinic and in the lab.

Sources cited:

• STAT News
• PYMNTS
• Heart & Lung
• Insilico Medicine
• Nature
• Emergency Radiology
• MedTech Dive
• Washington Post
• Axios
• FDA's AI-enabled medical device list

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.